Provided are a clinical-grade autologous bronchial basal cell, a deliverable formulation thereof, and a preparation process. The preparation process comprises the following steps: acquiring and digesting an in vitro active bronchoscopic brushed-off biopsy tissue, and collecting cells after digestion is terminated; plating the digested cells on a culture plate pre-coated with feeder layer cells, collecting the cultured cells to perform amplification culture on a culture plate pre-coated with feeder layer cells, and when the cells grow to cover 50%-90% of the surface area of the culture plate, performing cell passage operation; and when passaged culture cells grow to cover 85%-95% of the surface area of a culture dish, digesting and collecting adhered cells, and washing. The clinical-grade bronchial basal cell prepared by this method can differentiate stably after the cells reach the lesion and significantly achieve the damaged lung tissue regeneration.

Provided are a clinical-grade autologous bronchial basal cell, a deliverable formulation thereof, and a preparation process. The preparation process comprises the following steps: acquiring and digesting an in vitro active bronchoscopic brushed-off biopsy tissue, and collecting cells after digestion is terminated; plating the digested cells on a culture plate pre-coated with feeder layer cells, collecting the cultured cells to perform amplification culture on a culture plate pre-coated with feeder layer cells, and when the cells grow to cover 50%-90% of the surface area of the culture plate, performing cell passage operation; and when passaged culture cells grow to cover 85%-95% of the surface area of a culture dish, digesting and collecting adhered cells, and washing. The clinical-grade bronchial basal cell prepared by this method can differentiate stably after the cells reach the lesion and significantly achieve the damaged lung tissue regeneration.

The present disclosure provides compositions and methods for regenerating airway stem cells, as well as methods for treating an airway disease (e.g., cystic fibrosis (CF)) in a subject using the regenerated airway stem cells.

The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain.

The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain.

Provided are fetal tissue cells or a fetal tissue extract which can effectively prevent or treat bone disorders or diseases.

Provided are fetal tissue cells or a fetal tissue extract which can effectively prevent or treat bone disorders or diseases.

Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

A production method for pluripotent stem cells is provided, the method including the following (a) and (b): (a) a process filling a culture container with a liquid medium and thereafter raising, the temperature of the liquid medium in the culture container to the temperature at which pluripotent stem cells can proliferate; and (b) a process seeding pluripotent stem cells in the liquid medium in the culture container and culturing the pluripotent stem cells in suspension.